The Generics Bulletin Podcast: Teva, Sandoz, Sawai and US Orange Book patents
Editorial Team Discusses Strategic Moves By Major Players And US Patent Listing Debate
Executive Summary
Generics Bulletin’s editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA’s Orange Book.
This edition of the Generics Bulletin podcast sees editor Dave Wallace, deputy editor Dean Rudge and reporters Urtė Fultinavičiūtė and Adam Zamecnik discuss recent strategic moves for Teva, Sandoz and Sawai as well as controversy over US patent listings in the US Food and Drug Administration’s Orange Book.
Generics Bulletin previously covered the latest developments in Teva’s strategy in an in-depth article. (Also see "A Year After ‘Pivot To Growth’, Teva Keeps Pushing Forward With Innovative Assets" - Generics Bulletin, 13 May, 2024.)
We also previously covered Sandoz’s most recent strategic moves in biosimilars. (Also see "Sandoz ‘Surfs The Biosimilars Wave’ Despite US Natalizumab Delay" - Generics Bulletin, 8 May, 2024.)
Sawai recently reported its annual results for its financial year ended 31 March. (Also see "Sawai Narrowly Misses Annual Sales Forecast For 2023" - Generics Bulletin, 21 May, 2024.)
And a recent study shed light on US patents filed after FDA approval. (Also see "Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds" - Generics Bulletin, 16 May, 2024.)